Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection:NORDynamIC trial and real-life experience

Autor: Waldenstrom, Jesper, Farkkila, Martti, Rembeck, Karolina, Norkrans, Gunnar, Langeland, Nina, Morch, Kristine, Pedersen, Court, Rauning Buhl, Mads, Nieminen, Urpo, Nuutinen, Hannu, Alsio, Asa, Holmstrom, Lars, Jungnelius, Rolf, Lund, Katarina, Rubensson, Anders, Torell, Erik, Westin, Johan, Lagging, Martin

Publikováno v: Waldenström, J, Färkkilä, M, Rembeck, K, Norkrans, G, Langeland, N, Mørch, K, Pedersen, C, Rauning Buhl, M, Nieminen, U, Nuutinen, H, Alsiö, Å, Holmström, L, Jungnelius, R, Lund, K, Rubensson, A, Torell, E, Westin, J & Lagging, M 2016, ' Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection : NORDynamIC trial and real-life experience ', Scandinavian Journal of Gastroenterology, vol. 51, no. 3, pp. 337-343 . https://doi.org/10.3109/00365521.2015.1087588

OBJECTIVE: Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::05192f0f987a6ac632c1746b37876747
https://portal.findresearcher.sdu.dk/da/publications/93a81492-a9f1-49eb-8da2-5ed55952a3f6